A drug can be safe. It can be effective. It can survive years of trials, endure regulatory review and arrive at the market carrying the bureaucratic equivalent of a gold medal. Then somebody at a payer asks a short question: why should we cover it? The clinical answer may run to hundreds of pages. The useful answer has to fit inside a meeting.
That compression problem is MEYA Health's business. The New Jersey agency sits between healthcare invention and healthcare adoption, where science collides with budgets, policy, workflow and human attention. It helps pharmaceutical, biotech, device, diagnostics and digital-therapeutics companies decide what evidence matters, which stakeholder needs it and how to turn it into something that can travel - a value story, a budget-impact model, a payer dossier, a field playbook, a workshop, a microsite.
Until 2026, the company was called PFG MedComm. Lalitha Priya Chandrashekhar started it as a solo consultancy in 2013, after working across pharmaceutical companies and agencies. The founding conviction was specific: market access belongs near the beginning of innovation, not in the anxious weeks before launch. Thirteen years later, the MEYA name gives that idea a brighter wrapper. The underlying task remains stubbornly practical. Make the value legible before the decision arrives.
“Without access, all you have is a fancy letter from the FDA and a lot of debt.”MEYA Health's blunt version of the problem
The first thing that failed was the complete answer
One of the agency's case studies begins with a pleasing corporate paradox. A top-20 pharmaceutical company had a payer value proposition for a legacy brand. It was comprehensive. It was also ineffective at framing the issues that mattered to health systems. The document contained plenty of information and too little hierarchy.
From a long payer proposition to six messages people could carry
MEYA researched health-system priorities, profiled stakeholders and interviewed them. The team reduced the proposition to six priority messages, then built customer leave-behinds, an account-manager playbook and a training workshop around the new structure.
This is the small, copyable idea inside a very specialized field: do not confuse completeness with usefulness. First find the decision-maker's live concern. Then give the person carrying your argument a limited set of messages and tools that can bend to the conversation. The deliverable follows the decision, not the reverse.
A testimonial on MEYA's site captures the behavioral hurdle. A global marketing director had reservations about whether a stakeholder value-story workshop could work virtually. Afterward, the director called it “incredibly engaging.” The format did not change the client's mind by being digital. It changed the client's mind by making the abstract story usable in a room.
A loop, not a launch checklist
MEYA packages its method as the trademarked 360° Approach to Access. The language is neat - anticipate, adapt, accomplish - but the important distinction is temporal. The company is not arguing that every project needs more tactics. It is arguing that access questions should appear while evidence plans, stakeholder strategies and launch choices can still change.
Anticipate
Map the landscape, evidence gaps, likely objections and people with influence.
Adapt
Revise the strategy as data, policy, competition and payer expectations shift.
Accomplish
Turn the strategy into tools, training and experiences that support a decision.
The service list underneath the loop is broad because the access problem is broad. On the evidence side sit literature reviews, claims analyses, HEOR planning, payer research and budget-impact models. Strategy covers pricing, reimbursement, policy, scenario planning and launch roadmaps. Engagement adds dossiers, advisory boards and training. Creative work gives the science a shape: messaging systems, slides, infographics, animation and digital experiences.
Most agencies can make some of those things. Many consultancies can recommend them. MEYA's differentiating claim is that a curated group of strategists, health economists, scientific writers and creatives handles the chain together. The business model is custom professional services, not software and not a standardized subscription. Each engagement is scoped around the barrier.
The method has prerequisites
Message design cannot manufacture missing clinical evidence, compel a payer to cover a product or rescue a strategy that begins after the consequential choices are fixed. It works when a client can expose its assumptions, involve the relevant stakeholders and change the plan when research contradicts the internal story.
The customer is a company. The audience is a system
MEYA sells to healthcare innovators, but its work is built for an unusually crowded audience. A payer cares about population impact and budget. A health system cares about workflow and outcomes. An employer may see uneven coverage and workforce cost. A provider needs clinical relevance. A patient needs a path that makes sense outside a conference room. The account manager in the middle needs enough fluency to adjust without improvising the science.
The agency's anonymized portfolio shows the range. For a top-10 diagnostics manufacturer entering emerging markets, it paired a landscape assessment with stakeholder maps, a value-story deck, customer profiles and global training workshops. For a women's-health device facing national-payer resistance, it examined clinical, economic and access barriers - including racial disparities and disease burden - then developed a payer value story and publication support. For a large pharmaceutical company's national sales meeting, it created personas, scripts and scenes so attendees could encounter customer mindsets rather than merely hear them described.
That last example explains why an access consultancy has a creative department. Facts rarely move through organizations in their raw state. They move as a remembered scenario, a well-timed chart, a phrase an account manager can retrieve under pressure. MEYA is in the business of preserving scientific rigor while changing the container.
The quiet advantage of having been small first
PFG MedComm added its multidisciplinary team in 2016, won its first Tier 1 pharmaceutical client in 2017 and expanded into medical devices in 2019. Work with the FemTech Lab ecosystem followed in 2021. The firm trademarked its approach and received minority-business certification in 2022, added women- and minority-owned business credentials, collected industry recognition, formalized ESG policies and finally changed its name.
The sequence matters. MEYA did not start with an elaborate model and search for a problem worthy of it. It accumulated a method from client work, then named the method, then renamed the company. Its public culture follows the same bias toward assembly: remote-first, flexible and organized around purpose-built teams rather than a static bench. Senior specialists are meant to stay close to the work, while regional experts extend the firm's view into Europe, Latin America, the Middle East, Africa and Asia-Pacific.
Healthcare loves a breakthrough story. Access is less cinematic. It is a sequence of meetings, evidence choices, coding questions, stakeholder objections and revised slides. Yet this is precisely where a promising therapy becomes either available or theoretical. MEYA Health has chosen that unglamorous hinge as its subject. The company makes complicated medicine easier to judge - not by making the decision simple, but by making the argument clear enough to enter the room.